CD38 and Miyoshi myopathy: Omicron-adapted vd5 moderately increased cross-protection in patients with MGUS and MM after SCT without IT, but not in MM after SCT with IT or progressed MM patients receiving anti-CD38 mAb (Figure 4D,F), similar to reports by Aleman et al. [17].